The aim of the study was to explore proteins in the blood of EoE patients, with a focus on variability at baseline, change with treatment, and whether pre-treatment plasma proteins can predict how patients respond to topical corticosteroid therapy (tCS). The joint global research efforts to support research on EoE and to better understand the disease over time is important for patients, healthcare and anyone trying to develop new treatments.

 

Professor Evan Dellon, together with Professor Arjan Breedenord and Dr Luc Biedermann, is part of Aqilion's Scientific Advisory Board with a focus on Aqilon's development of AQ280, a selective JAK1 inhibitor, as a new treatment for EoE. The three members of the Scientific Advisory Board are all three well-known KOLs in EoE and they are involved in both the design of Aqilion's clinical studies and the company's research. Collaborations with the Scientific Advisory Board aim to produce new data that can be presented at scientific conferences and in publications.

 

Sarah Fredriksson, CEO of Aqilion, comments:

 

–          The more the collected research contributes to understanding EoE and facilitating diagnosis, follow-up and treatment, the more value is added to the patient and the care. We are happy and proud of the collaboration that contributes with new data to research in EoE.The studies also support us in the development of AQ280 and it is strategically important and valuable for the operational activities to follow the latest research findings closely through an in-depth collaboration with our Scientific Advisory Board.

For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com